Quick Answer
Xilio Therapeutics, Inc. reported R&D Expense of $56.04 million for fiscal year 2025.
Xilio Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $56.04M | +36.0% |
| 2024 | $41.21M | -21.0% |
| 2023 | $52.14M | -11.9% |
| 2022 | $59.20M | +15.7% |
| 2021 | $51.19M | +16.6% |
| 2020 | $43.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.32M | +33.1% | -6.6% |
| June 30, 2025 | $15.33M | +36.7% | +85.5% |
| March 31, 2025 | $8.27M | -20.5% | -23.2% |
| September 30, 2024 | $10.76M | -2.6% | -4.1% |
| June 30, 2024 | $11.22M | -15.1% | +7.8% |
| March 31, 2024 | $10.40M | -35.5% | -5.9% |
| September 30, 2023 | $11.05M | -15.2% | -16.4% |
| June 30, 2023 | $13.22M | -18.6% | -18.1% |
- Xilio Therapeutics, Inc. showed an increase of +36.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s r&d expense has grown by 27.6% (from $43.91 million to $56.04 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: